ArticlemAbs
Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies.
Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Aptamers in Ocular Disease Therapy and Drug Delivery: Current Progress and Future Opportunities.Current therapeutic research, clinical and experimental · 2026Review
- CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.Molecular therapy. Advances · 2026Article
- A multiscale PBPK-PD model of oxytocin-induced uterine excitation and contraction.The Journal of physiology · 2026Article
- Glypican-3 targeted radiopharmaceuticals for hepatocellular carcinoma: a review of molecular platforms.EJNMMI research · 2026Review
- SPECT as a translational non-invasive method to assess occupancy of the tissue transglutaminase-2 by zampilimab in the mouse lung.Respiratory research · 2026Article
- A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies.CPT: pharmacometrics & systems pharmacology · 2026Article
- Flycodes enable simultaneous preclinical analysis for dozens of antibodies in single cassette-dosed mice.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling.EJNMMI research · 2025Article
- Quantification of endogenous and therapeutic IgG crossing the kidney barrier from bloodstream to urine.Frontiers in pharmacology · 2025Review
- The Chorioallantoic Membrane as a Platform for Developing Vascularized Cell Macroencapsulation Devices.Journal of tissue engineering and regenerative medicine · 2025Article
- Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats.Frontiers in immunology · 2025Review
- Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Lateral Flow-Based Skin Patch for Rapid Detection of Protein Biomarkers in Human Dermal Interstitial Fluid.ACS sensors · 2024Article
- A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- A novel approach to quantitate biodistribution and transduction of adeno-associated virus gene therapy using radiolabeled AAV vectors in mice.Molecular therapy. Methods & clinical development · 2024Article
- A Bispecific Modeling Framework Enables the Prediction of Efficacy, Toxicity, and Optimal Molecular Design of Bispecific Antibodies Targeting MerTK.The AAPS journal · 2024Article
- Unveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in antibody engineering have enabled the construction of novel molecular formats in diverse shapes and sizes, providing new opportunities for biologic therapies and expanding the need to understand how various structural aspects affect their distribution properties. To assess the effect of antibody size on systemic pharmacokinetics (PK) and tissue distribution with or without neonatal Fc receptor (FcRn) binding, we evaluated a series of non-mouse-binding anti-glycoprotein D monoclonal antibody formats, including IgG [~150 kDa], one-armed IgG [~100 kDa], IgG-HAHQ (attenuated FcRn binding) [~150 kDa], F(ab')
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.